Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has announced that several of its drugs are expected to be selected in the continuation procurement organized by the National Organization for Drug Procurement, which is set to stabilize or further reduce prices while enhancing the selection power of medical institutions [1][4]. Group 1: Selected Drugs - The company participated in the continuation procurement for drugs whose agreements have expired, with several key products expected to be selected, including those that rank among the top five in revenue [1][2]. - The procurement cycle for the selected drugs will last until December 31, 2028 [1]. Group 2: Financial Impact - In 2024, the sales revenue for Valsartan Hydrochlorothiazide Tablets is projected to be 517 million yuan, accounting for 4.61% of the total revenue; for Nifedipine Controlled-Release Tablets, it is expected to be 147 million yuan, or 1.31% [3]. - For the first three quarters of 2025, the sales revenue for Valsartan Hydrochlorothiazide Tablets is estimated at 426 million yuan, representing 5.14% of total revenue; for Nifedipine Controlled-Release Tablets, it is projected at 138 million yuan, or 1.67% [3]. Group 3: Market Dynamics - The continuation procurement is expected to maintain price stability or further decrease prices, allowing medical institutions greater choice among selected suppliers, which may help ensure continuity in clinical medication and reduce risks associated with drug switching [4]. - Although the selection may lead to a decrease in overall sales revenue, it is anticipated that the company can solidify its existing market share and potentially increase its market penetration due to its brand influence and reliable supply capabilities [4].

Core Points - The DT New Leaf Award is a global, professional, and comprehensive award focused on innovation in the bio-based sector, often referred to as the "Oscar of the bio-based industry" [2] - The award features four categories: Innovation Material Award, Innovation Application Award, Most Commercially Valuable Award, and Innovative Industry Solution Award [2] - The deadline for free registration is March 13 [2] Group 1: Participating Companies and Products - Over 40 listed and representative companies have registered for the 2026 DT New Leaf Award, including major players in bio-based materials and applications such as Wanhua Chemical, Shuangqiang Technology, and Yutong Technology [3] - Wanhua Chemical (600309) is a leading global chemical new materials company and has established a bio-based polyurethane industry chain [5] - Shuangqiang Technology (001211) is recognized as the first stock of chopsticks in China and has signed a contract to jointly develop bamboo-based composite materials with Ningbo Materials [7] - China Resources Double Crane (600062) has its 1,4-butanediamine included in the "Ministry of Industry and Information Technology's list of landmark bio-manufacturing products" [9] Group 2: Selected Products and Innovations - Wanhua Chemical's PCDL product, made from dimethyl carbonate, can be produced through carbon capture processes and has excellent mechanical properties [11] - Shuangqiang Technology's bamboo-based composite logistics pallets are cost-effective, priced at only 60%-70% of traditional plastic pallets with similar performance [12] - Yutong Technology is advancing the development of non-wood fibers and biodegradable materials, including eco-friendly cellulose films and plant-based cat litter [13] - Lifebio is a global leader in PEF & FDCA and has a production line for FDCA with an investment of 1 billion yuan, expected to yield an annual output of 15,000 tons [16] Group 3: Innovations and Technologies - Zhongke Guosheng is a representative enterprise in the HMF-FDCA-PEF full industry chain and has completed a 200 million yuan A+ round financing [17] - Fengyuan Bio is recognized as a "chain leader" in the bio-based materials industry, utilizing non-grain technology to convert straw into mixed sugars at a cost significantly lower than corn glucose [19] - Guwei Yuan Chuang is the first global company to focus on non-grain bio-based succinic acid production and has received the first ISCC PLUS certification for its products [21] - The innovative use of plant fiber materials in products like Ecocoon and PEF-based fibers demonstrates advancements in sustainable materials with multiple natural functions [23][24] Group 4: Award Evaluation and Process - The evaluation criteria for the awards include technical innovation, application innovation, functionality, commercial value, and sustainability [111] - The total score for the awards is 100 points, with online voting accounting for 20 points and expert reviews for 80 points [110] - The award process includes registration, online voting, and expert evaluations, culminating in a ceremony on May 21 [110]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－010 华润双鹤药业股份有限公司 关于公司部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 2026 年 2 月 9 日，华润双鹤药业股份有限公司(以下简称"公司") 及部分下属子公司参加了国家组织集采药品协议期满品种接续采购 办公室(以下简称"接续采购办公室")组织的集采药品协议期满品种 接续采购(以下简称"本次接续采购")。根据接续采购办公室于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中 选结果公示》，公司部分药品拟中选本次接续采购。现将相关情况公 告如下： | 拟中选企业 | 品种名称 | 药品适应症 | 规格 | | --- | --- | --- | --- | | 华润双鹤药业 股份有限公司 | 缬沙坦氢氯 噻嗪片 | 治疗单一药物不能充分控制血压的轻-中 | 每片含缬沙坦 80mg，氢氯噻 | | | | 度原发性高血压 | 嗪 12.5mg | ...

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for pharmaceutical products, with some of its drugs expected to be selected in the upcoming procurement results, which will be implemented by the end of March 2026 [1][2] Group 1: Company Performance - In the first three quarters of 2025, the sales revenue of Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of the total revenue [1] - The sales revenue of Nifedipine Controlled-Release Tablets was 138 million yuan, representing 1.67% of the total revenue [1] - The sales revenue of Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of the total revenue [1] - The sales revenue of Nifedipine Sustained-Release Tablets (II) was 108 million yuan, accounting for 1.30% of the total revenue [1] - The sales revenue of Irbesartan Dispersible Tablets was 79 million yuan, which is 0.95% of the total revenue [1] Group 2: Industry Context - The upcoming procurement process aims to maintain stable or decreasing prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces the risk of medication switching due to centralized procurement [2] - Although the selection may lead to a decrease in overall sales revenue, it is expected to solidify the company's existing market share, with potential for increased market penetration due to brand influence and reliable supply capabilities [2]

Core Viewpoint - China Resources Double Crane announced that the company and some subsidiaries participated in the national organized procurement for drugs whose agreements are expiring, with several drugs expected to be selected for procurement [1] Group 1: Selected Drugs and Revenue Impact - The main drugs expected to be selected include: - Valsartan and Hydrochlorothiazide Tablets with projected sales revenue of 517 million yuan, accounting for 4.61% of the 2024 annual revenue [1] - Nifedipine Controlled-Release Tablets with projected sales revenue of 147 million yuan, accounting for 1.31% of the 2024 annual revenue [1] - Enoxaparin Sodium Injection with projected sales revenue of 128 million yuan, accounting for 1.14% of the 2024 annual revenue [1] - Nifedipine Sustained-Release Tablets (II) with projected sales revenue of 118 million yuan, accounting for 1.05% of the 2024 annual revenue [1] - Irbesartan Dispersible Tablets with projected sales revenue of 110 million yuan, accounting for 0.98% of the 2024 annual revenue [1]

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in this procurement [1][2]. Group 1: Company Performance - In the first three quarters of 2025, the sales revenue for Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of total revenue [1]. - Sales revenue for Nifedipine Controlled Release Tablets was 138 million yuan, representing 1.67% of total revenue [1]. - Sales revenue for Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of total revenue [1]. - Sales revenue for Nifedipine Sustained Release Tablets (II) was 108 million yuan, which is 1.30% of total revenue [1]. - Sales revenue for Irbesartan Dispersible Tablets was 79 million yuan, accounting for 0.95% of total revenue [1]. Group 2: Industry Context - The procurement process is expected to stabilize or further reduce prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces risks associated with drug switching due to centralized procurement [2]. - Although the selection may lead to a decrease in overall sales amounts, it is anticipated to solidify existing market shares, with the company likely to enhance its market share due to its brand influence and reliable supply capabilities [2].

证券代码：600062 证券简称：华润双鹤 公告编号：临2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需求，强化营销体系建设，推进营销资源整 合，组建营销管理中心。 11票同意，0票反对，0票弃权。 特此公告。 华润双鹤药业股份有限公司 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章程》的有关规定。本次会议通知和材 料于2026年2月2日以邮件方式向全体董事发出，会议于2026年2月5日以通讯方式召开。出席会议的董事 应到11名，亲自出席会议的董事11名。 二、董事会会议审议情况 1、关于2026年境外佣金预算的议案 11票同意，0票反对，0票弃权。 2、关于组建营销管理中心的议案 一、董事会会议召开情况 董 事 会 2026年2月6日 ...

第十届董事会第十七次会议 2026 年 2 月 5 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 1、关于2026年境外佣金预算的议案 11 票同意，0 票反对，0 票弃权。 2、关于组建营销管理中心的议案 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需 求，强化营销体系建设，推进营销资源整合，组建营销管理中心。 11 票同意，0 票反对，0 票弃权。 特此公告。 华润双鹤药业股份有限公司 董 事 会 一、董事会会议召开情况 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2026 年 2 月 2 日以邮件方 式向全体董事发出，会议于 2026 年 2 月 5 日以通讯方式召开。出席 会议的董事应到 11 名，亲自出席会议的董事 11 名。 二、董事会会议审议情况 2026 年 2 月 6 日 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：华润双鹤获证监会批复，同意其向专业投资者公开发行面值总额不超过30亿元的 公司债券。 公司公告汇总：全资子公司复方醋酸钠林格注射液获药品注册证书，视同通过一致性评价。 华润双鹤关于向专业投资者公开发行公司债券获得中国证监会批复的公告 华润双鹤药业股份有限公司于近日收到中国证券监督管理委员会出具的《关于同意华润双鹤药业股份有 限公司向专业投资者公开发行公司债券注册的批复》（证监许可[2026]118号）。中国证监会同意公司 向专业投资者公开发行面值总额不超过30亿元的公司债券。该批复自同意注册之日起24个月内有效，公 司可在注册有效期内分期发行公司债券。公司将按有关法律法规、批复要求及公司股东会授权办理本次 公司债券发行的相关事宜，并及时履行信息披露义务。 华润双鹤关于全资子公司西安京西双鹤药业有限公司复方醋酸钠林格注射液获得药品注册证书的公告 华润双鹤全资子公司西安京西双鹤药业有限公司收到国家药监局颁发的复方醋酸钠林格注射液《药品注 册证书》，规格为250ml、500ml ...

Group 1 - China Resources Double Crane and Limin Pharmaceutical were fined 1 million and 3 million yuan respectively for producing sodium bicarbonate injection that failed to meet key quality indicators, specifically "visible foreign matter" and "pH value" [1][5] - The penalties were based on violations of Article 98 of the Drug Administration Law, which outlines strict regulations for drug production [1] - The specific batches involved were identified as 24120602 for China Resources Double Crane and K24110334 for Limin Pharmaceutical, with a total of 23,000 and 30,464 units respectively being deemed non-compliant [3][5] Group 2 - The fines imposed on Limin Pharmaceutical included the confiscation of all non-compliant products and a recovery of illegal gains amounting to 197.5 yuan [3] - For China Resources Double Crane, the total penalty reached 3.0317 million yuan, including the confiscation of illegal gains of 93,300 yuan, bringing the total to 3.125 million yuan [6] - Both companies were penalized following a notice from the National Medical Products Administration regarding 28 batches of non-compliant drugs, highlighting the regulatory scrutiny in the pharmaceutical industry [6]